Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAFV600E Mutant Glioma
Micah J. Maxwell(Johns Hopkins University), Eric H. Raabe(Johns Hopkins University), Michael Schnaubelt(Johns Hopkins University), Antje Arnold(Johns Hopkins University), David Clark(Johns Hopkins University), Jeffrey Rubens(Johns Hopkins University), Heather Sweeney(Johns Hopkins University), T. Mamie Lih(Johns Hopkins University), Hui Zhang(Zhengzhou Central Hospital), Lijun Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Charles G. Eberhart(The University of Texas MD Anderson Cancer Center)
Cited by 7
Related Papers
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations
|Science|2011|1.1k
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711